Literature DB >> 6140752

Early intervention, time-limited, targeted pharmacotherapy of schizophrenia.

W T Carpenter, D W Heinrichs.   

Abstract

A growing appreciation of the risks of long-term, continuous neuroleptic use in the aftercare of schizophrenic patients has led to a search for alternative strategies. The authors report their experiences with the clinical strategy of "targeted" medication, in which patients are followed drug free until prodromal signs of impending relapse appear. Medication is then initiated to abort the impending episode and discontinued when patients restabilize clinically. Preliminary experience suggests that control of schizophrenic symptomatology comparable to that obtained with maintenance drugs can be achieved with a marked reduction in medication use when the targeted strategy is applied in the context of a broad-based program of psychosocial intervention based on a comprehensive medical model.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140752     DOI: 10.1093/schbul/9.4.533

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  10 in total

1.  Soteria Berne: an innovative milieu therapeutic approach to acute schizophrenia based on the concept of affect-logic.

Authors:  Luc Ciompi; Holger Hoffmann
Journal:  World Psychiatry       Date:  2004-10       Impact factor: 49.548

2.  Development of clinical methods for utilization review in psychiatric day treatment.

Authors:  K G Terkelsen; R H McCarthy; R L Munich; B E Hurley
Journal:  J Ment Health Adm       Date:  1994

3.  Ethical concerns in schizophrenia research: looking back and moving forward.

Authors:  Scott T Wilson; Barbara Stanley
Journal:  Schizophr Bull       Date:  2005-11-10       Impact factor: 9.306

Review 4.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 5.  Antipsychotic dosing: found in translation.

Authors:  Gary Remington; Gagan Fervaha; George Foussias; Ofer Agid; Peter Turrone
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

6.  Multidimensional study of the outcome of schizophrenic patients 1 year after clinic discharge. Predictors and influence of neuroleptic treatment.

Authors:  W Gaebel; A Pietzcker
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

Review 7.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

8.  Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT.

Authors:  Andrew I Gumley; Simon Bradstreet; John Ainsworth; Stephanie Allan; Mario Alvarez-Jimenez; Maximillian Birchwood; Andrew Briggs; Sandra Bucci; Sue Cotton; Lidia Engel; Paul French; Reeva Lederman; Shôn Lewis; Matthew Machin; Graeme MacLennan; Hamish McLeod; Nicola McMeekin; Cathy Mihalopoulos; Emma Morton; John Norrie; Frank Reilly; Matthias Schwannauer; Swaran P Singh; Suresh Sundram; Andrew Thompson; Chris Williams; Alison Yung; Lorna Aucott; John Farhall; John Gleeson
Journal:  Health Technol Assess       Date:  2022-05       Impact factor: 4.106

9.  Prognosis of the course of schizophrenic psychoses compared to other psychiatric illnesses. Catamnestic treatment and outcome 1 year after discharge.

Authors:  W Gaebel; A Pietzcker
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

10.  Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.

Authors:  K Kistrup; J Gerlach; T Aaes-Jørgensen; N E Larsen
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.